Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 23

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 23
---
 days (provided that such breach is curable within 90 days), or if we become bankrupt or insolvent, or if our business is placed in
the hands of a receiver, assignee or trustee, because Yissum has the right to terminate this license pursuant to the terms of the Yissum
License Agreements. This could result in inability of the Company to develop, manufacture and sell products that are covered by the licensed
technology pursuant to the Yissum License Agreements (the “Licensed Technology”) and could also result in competitors gaining
access to Licensed Technology.

The Israeli Contract Law (Remedies for Breach
of Contract) 1970, defines the term “material breach” as a breach, with regards to which, it may be assumed that a reasonable
person would not have entered into the specific agreement had that person foreseen the breach and the outcome thereof, or a breach which
is specifically defined as material in the agreement. Acts that may constitute a material breach of the license agreement by us may include,
for example: the granting of sublicenses not in compliance with the provisions of the license agreement, a breach of our obligations
to pay required license payments or royalties and provide the necessary reports with respect thereto, a breach of our obligations not
to disclose or misuse certain confidential information of Yissum, and a breach of our obligations to develop and commercialize the Licensed
Technology (including our obligation to fund certain research and development activities) and to conduct patent prosecution and maintenance.

Uncertainty surrounding our option to obtain an exclusive license to the Nano-Candesartan program, including a disagreement with Yissum regarding the status and timing of the option exercise period, could limit our development pipeline and adversely affect our business.

In 2023, we entered into an option agreement
with Yissum relating to a preclinical ARB formulation program. Under this agreement, the Company is entitled to receive a final scientific
report following completion of four designated preclinical studies, after which a 90-day option exercise period and 120 days to negotiate
an exclusive license.

However, in November 2025, Yissum informed
the Company that, in its view, the option exercise period had already commenced and expired, based on a report Yissum considers to be
the final scientific report, which Yissum claims was delivered in September 2024. The Company disagrees with this position, noting that
(i) the report delivered in 2024 did not include the components specified in